Home » Stocks » IGMS

IGM Biosciences, Inc. (IGMS)

Stock Price: $103.57 USD 6.42 (6.60%)
Updated Jan 19, 2021 3:07 PM EST - Market open
Market Cap 3.10B
Revenue (ttm) n/a
Net Income (ttm) -71.55M
Shares Out 30.65M
EPS (ttm) -26.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $103.57
Previous Close $97.15
Change ($) 6.42
Change (%) 6.60%
Day's Open 99.99
Day's Range 98.79 - 106.71
Day's Volume 131,065
52-Week Range 31.51 - 106.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

STOCKHOLM, Jan. 12, 2021 /PRNewswire/ -- Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, In...

GlobeNewsWire - 1 week ago

- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -

GlobeNewsWire - 1 week ago

MOUNTAIN VIEW, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodi...

The Motley Fool - 4 weeks ago

Short squeezes don't typically live up to their expectations.

GlobeNewsWire - 1 month ago

MOUNTAIN VIEW, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the closing of its upsized underwritten public offering of 1,221,224 shares ...

GlobeNewsWire - 1 month ago

MOUNTAIN VIEW, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its com...

GlobeNewsWire - 1 month ago

MOUNTAIN VIEW, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $150 million of shares of its common stock and, ...

GlobeNewsWire - 1 month ago

- 9 of 14 P atients S howed R eduction in T umor S ize, I ncluding T wo R ecently R eported C omplete R esponses -

GlobeNewsWire - 1 month ago

MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodi...

GlobeNewsWire - 1 month ago

MOUNTAIN VIEW, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodi...

GlobeNewsWire - 2 months ago

MOUNTAIN VIEW, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodi...

GlobeNewsWire - 2 months ago

MOUNTAIN VIEW, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- - Initial D ata from Phase 1 T rial of IGM-2323 in R elapsed/ r efractory N on-Hodgkin's L ymphoma to be Presented at the 62nd American...

GlobeNewsWire - 2 months ago

- Abstract Shows Encouraging Safety and Cytokine Release Data, Preservation of T cell Function and Repeatable T cell Activation - - Abstract Shows Encouraging Safety and Cytokine Release Data,...

GlobeNewsWire - 3 months ago

MOUNTAIN VIEW, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibod...

GlobeNewsWire - 3 months ago

- Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies - - Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies -

GuruFocus - 3 months ago

Analysts also positive on Charles River, Gilead and Horizon Therapeutics

Zacks Investment Research - 4 months ago

IGM Biosciences (IGMS) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

24/7 Wall Street - 4 months ago

The firms that we cover on Wall Street increasingly are starting to agree that the volatility the stock market is encountering now, and the beating the economy has taken this year, should cont...

Other stocks mentioned: CRL, GILD, HZNP
Benzinga - 4 months ago

  Insider buying can be an encouraging signal for potential investors when markets are near all-time highs.

Other stocks mentioned: KDP, XRX, CAR, GBDC, KOD
GlobeNewsWire - 4 months ago

MOUNTAIN VIEW, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antib...

GlobeNewsWire - 5 months ago

­IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the second...

GlobeNewsWire - 5 months ago

MOUNTAIN VIEW, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibo...

GlobeNewsWire - 8 months ago

- Companies to utilize proprietary platforms to discover, develop, and manufacture potential  therapeutic antibodies to combat ongoing COVID-19 pandemic -

The Motley Fool - 8 months ago

Clinical trial successes could send shares of these drugmakers screaming higher.

Other stocks mentioned: BCYC, BTAI
Seeking Alpha - 9 months ago

IGM Biosciences, Inc. (IGMS) CEO Fred Schwarzer on Q4 2019 Results - Earnings Call Transcript

24/7 Wall Street - 1 year ago

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in th...

Other stocks mentioned: CDMO, ENDP, ILMN, ISEE, KOD, MYL, NVCN, PCRX, PFE, XFOR
GlobeNewsWire - 1 year ago

- Expert in the research and development of apoptotic pathways and antibody drug conjugates - - Expert in the research and development of apoptotic pathways and antibody drug conjugates -

ETF Trends - 1 year ago

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for inve...

Other stocks mentioned: BYND, CRTX, INMD, KRTX, NXTC, PLMR, SWAV, TPTX

About IGMS

IGM Biosciences, a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2019
CEO
Fred M. Schwarzer
Employees
103
Stock Exchange
NASDAQ
Ticker Symbol
IGMS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for IGMS stock is "Buy." The 12-month stock price forecast is 89.56, which is a decrease of -13.52% from the latest price.

Price Target
$89.56
(-13.52% downside)
Analyst Consensus: Buy